Last reviewed · How we verify

Ammonul (SODIUM BENZOATE)

FDA-approved approved Small molecule Quality 65/100

Ammonul works by inhibiting the enzyme carbonic anhydrase 2, which helps to reduce ammonia levels in the body.

Ammonul (Sodium Benzoate) is a small molecule drug that targets carbonic anhydrase 2. It is a sodium benzoate drug class, FDA approved in 1987 for the treatment of apnea in the newborn and hyperammonemia. The commercial status of Ammonul is not publicly available. Key safety considerations include the potential for adverse effects, although specific details are not provided. As a sodium benzoate, it is a generic drug class.

At a glance

Generic nameSODIUM BENZOATE
Drug classsodium benzoate
TargetCarbonic anhydrase 2
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved
First approval1987

Mechanism of action

Think of ammonia like a toxic gas in your body. Carbonic anhydrase 2 helps to make more ammonia. Ammonul blocks this enzyme, so less ammonia is made, which can help treat conditions like hyperammonemia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: